Positive results from DREAMM-7 head-to-head Phase 3 trial for Blenrep in relapsed/refractory multiple myeloma.
GSK today announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial met its primary endpoint of progression-free…